Abingdon Health plc is an international developer, contract manufacturer and regulatory-services provider focused on rapid diagnostic and lateral-flow tests, headquartered on the York Biotech Campus. The company offers a full-service CDMO platform that takes customer assays from design through regulatory approval and volume production. Recent commercial activity includes a €2 million contract with a European biotech firm to progress a companion diagnostic point-of-care test, the roll-out of pregnancy-testing kits into Germany, Poland and Austria, and a collaboration with a Dutch company to improve bird-flu testing. In 2023 it also created Abingdon Health USA to increase manufacturing capacity and better serve North American clients. Management reports that both the U.S. subsidiary and the CDMO offering are gaining strong traction with customers. Several major contract wins are expected to translate into new revenue streams, and the company has turned to the capital markets to fund larger projects and sustain its expansion. Although the article provides no specific revenue figures, the pipeline of signed contracts suggests growing commercial momentum.

Total raised

$19M

Funding rounds

5

Latest round

Equity

Latest activity

Oct 2025